S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:NVAX

Novavax - NVAX Stock Forecast, Price & News

$11.23
-0.78 (-6.49%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$11.18
$12.28
50-Day Range
$8.86
$17.61
52-Week Range
$8.75
$101.39
Volume
6.47 million shs
Average Volume
6.84 million shs
Market Capitalization
$881.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$104.63

Novavax MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
723.7% Upside
$92.50 Price Target
Short Interest
Bearish
39.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
-0.04mentions of Novavax in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.49) to ($4.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

666th out of 1,025 stocks

Biological Products, Except Diagnostic Industry

107th out of 168 stocks

NVAX stock logo

About Novavax (NASDAQ:NVAX) Stock

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Stock News Headlines

MarketBeat Week in Review – 1/30 - 2/3 (NVAX)
The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shot
Novavax Shares Jumped in January While Others Slipped (NVAX)
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
2 Biotechs Making Waves With A Single Product in their Pipeline (NVAX)
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
Novavax (NASDAQ:NVAX) Trading Up 10.6%
Novavax (NASDAQ:NVAX) Stock Price Down 6%
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Novavax: The Vaccine Battle Continues With Gavi
3 Great Growth Stocks Down 20% or More to Buy Now
Could Novavax Stock Help You Become a Millionaire?
With This Big Transition Ahead, Is Novavax a Buy?
Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Company Calendar

Last Earnings
11/08/2022
Today
2/05/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,541
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$92.50
High Stock Price Forecast
$198.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+831.7%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-1,743,750,000.00
Pretax Margin
-70.33%

Debt

Sales & Book Value

Annual Sales
$1.15 billion
Book Value
($4.65) per share

Miscellaneous

Free Float
76,855,000
Market Cap
$881.56 million
Optionable
Optionable
Beta
1.73

Social Links


Key Executives

  • John C.s Jacobs
    President, Chief Executive Officer & Director
  • Richard Crowley
    Chief Operating Officer & Executive Vice President
  • James Patrick Kelly
    Chief Financial Officer, Treasurer & Executive VP
  • Gale E. Smith
    Chief Scientist & Senior Vice President-Discovery
  • Gregory M. GlennGregory M. Glenn
    President-Research & Development













NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVAX, but not buy additional shares or sell existing shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price forecast for 2023?

7 equities research analysts have issued 1 year price objectives for Novavax's stock. Their NVAX share price forecasts range from $27.00 to $198.00. On average, they expect the company's share price to reach $92.50 in the next twelve months. This suggests a possible upside of 723.7% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2023?

Novavax's stock was trading at $10.28 on January 1st, 2023. Since then, NVAX stock has increased by 9.2% and is now trading at $11.23.
View the best growth stocks for 2023 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($2.15) earnings per share for the quarter, missing analysts' consensus estimates of $2.21 by $4.36. The biopharmaceutical company had revenue of $734.58 million for the quarter, compared to analyst estimates of $555.50 million. Novavax's revenue for the quarter was up 310.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($4.31) EPS.

When did Novavax's stock split?

Novavax shares reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.00 billion-$2.00 billion, compared to the consensus revenue estimate of $2.04 billion.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by many different retail and institutional investors. Top institutional shareholders include Shah Capital Management (0.91%), Simplex Trading LLC (0.00%), Wolverine Asset Management LLC (0.00%), SG Americas Securities LLC (0.16%), Mendel Capital Management LLC (0.03%) and DekaBank Deutsche Girozentrale (0.03%). Insiders that own company stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends
.

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $11.23.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $881.56 million and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis.

How many employees does Novavax have?

The company employs 1,541 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 2/5/2023 by MarketBeat.com Staff